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To study whether individual HLA class I alleles are used preferentially or equally in human virus-specific CTL responses, the
contribution of individual HLA-A and -B alleles to the human influenza virus-specific CTL response was investigated. To this end,
PBMC were obtained from three groups of HLA-A and -B identical blood donors and stimulated with influenza virus. In the
virus-specific CD8 T cell population, the proportion of IFN-- and TNF--producing cells, restricted by individual HLA-A and
-B alleles, was determined using virus-infected C1R cells expressing a single HLA-A or -B allele for restimulation of these cells.
In HLA-B*2705- and HLA-B*3501-positive individuals, these alleles were preferentially used in the influenza A virus-specific CTL
response, while the contribution of HLA-B*0801 and HLA-A*0101 was minor in these donors. The magnitude of the HLA-
B*0801-restricted response was even lower in the presence of HLA-B*2705. C1R cells expressing HLA-B*2705, HLA-A*0101, or
HLA-A*0201 were preferentially lysed by virus-specific CD8 T cells. In contrast, the CTL response to influenza B virus was
mainly directed toward HLA-B*0801-restricted epitopes. Thus, the preferential use of HLA alleles depended on the virus
studied. The Journal of Immunology, 2004, 172: 4435–4443.
C ytotoxic T lymphocytes have been shown to play an im-portant role in the control and clearance of virus infec-tions, including those caused by influenza virus (1, 2).
Although a large number of peptides are generated during process-
ing of viral proteins in infected cells, only some of these peptides
are ultimately presented by MHC class I molecules and recognized
by specific CTL. This limited recognition of a small number of
dominant CTL epitopes has been termed immunodominance (3–5).
Usually immunodominance is defined using a number of synthetic
peptides representing known CTL epitopes, without taking into
account the full repertoire of potential epitopes. Little information
is available on the complete repertoire of CTL epitopes of viral
pathogens and the corresponding HLA alleles presenting these
epitopes to specific CTL. Using transient HLA expression systems,
HLA-A11, HLA-B8, and HLA-B44 were identified as the pre-
ferred restriction elements in the CTL response to EBV (6–9).
These studies also demonstrated that the HLA-A1-restricted EBV-
specific CTL response is of minor importance.
In most studies addressing the contribution of individual HLA
molecules in CTL responses, synthetic peptides representing
known CTL epitopes have been used (10–15). It has been shown
recently that the magnitude and specificity of influenza A virus-
specific CTL response, using nine peptide analogues of known
influenza A virus CTL epitopes, are related to the MHC class I
haplotype of individuals (15). In this study, it was demonstrated
that the magnitude of the influenza A virus-specific CTL response
was highest in HLA-A*0201-positive individuals. This association
was thought to be related to recognition of an HLA-A*0201-re-
stricted immunodominant epitope (M158–66) from the matrix pro-
tein. Thus, it might be expected that if CTL responses were ana-
lyzed by individual HLA-A and -B alleles, the majority of CTL
would recognize influenza A virus-infected targets in a HLA-
A*0201-restricted fashion. Although the use of synthetic peptides
provides some information on HLA usage in CTL response, this
approach has limitations and does not account for the full reper-
toire of epitopes presented by infected cells.
In the present study, the contribution of individual HLA-A and
-B alleles to the CTL response against a model viral pathogen was
investigated. To this end, influenza virus-specific memory CTL
response was studied, using C1R cells expressing a single HLA-A
or -B allele and influenza virus-stimulated PBMC obtained from
three groups of healthy blood donors with defined HLA class I
haplotypes. Between groups, the individuals shared two or three of
the four HLA-A and -B alleles. Intracellular IFN- and TNF-
staining was used for the quantification of virus-specific CTL re-
stricted by a single HLA-A or -B allele, and the lytic capacity of
these cells was determined in classical 51Cr release assays.
We found that individual HLA alleles were not used to the same
extent and that in each group of HLA-typed individuals a hierarchy
existed between HLA alleles. Especially HLA-B*2705 and HLA-
B*3501 were found to be preferred alleles in the influenza A virus-
specific CTL response. The preferential HLA usage was found to
depend on the type of influenza virus (A or B) studied.
Materials and Methods
Cells
PBMC obtained from 13 healthy blood donors (Table I) were isolated
between 1999 and 2002 using Lymphoprep (Nycomed, Oslo, Norway) gra-
dient centrifugation and cryopreserved at135°C. Three groups of donors,
aged between 35 and 50 years of age, were selected according to serolog-
ical homology within the A locus and B locus of HLA class I molecules
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(Table I). Genetic subtyping was performed in the laboratory for Histo-
compatibility and Immunogenetics at the Sanquin Bloodbank Rotterdam
using a commercial typing system (GenoVision, Vienna, Austria). All do-
nors had serum Abs against one or more influenza A virus strains, mea-
sured by hemagglutination inhibition assay, indicative of one or more ex-
posures in the past. Also, three of the four donors tested for influenza B
virus-specific CTL immunity (group II) had influenza B virus-specific Abs.
Of each group of HLA-A- and -B-matched donors, EBV-transformed B
lymphoblastoid cell lines (BLCL)3 were produced, as described previously
(16). BLCL were cultured in RPMI 1640 medium supplemented with 10%
FCS, 2 mM glutamine, 100 g/ml streptomycin, and 100 IU/ml penicillin
(R10F).
Hmy2-C1R (C1R) is a human BLCL with low expression of endoge-
nous HLA-Cw4 (17, 18), but no expression of HLA-A or -B alleles. Con-
trol C1R cells and those transfected with individual HLA-A or -B genes
were cultured in R10F. The transfected C1R cells were kindly provided by
several investigators: HLA-A1-transfected C1R cell line by P. Cresswell
(Section of Immunobiology, Howard Hughes Medical Institute, Yale Uni-
versity School of Medicine, New Haven, CT), HLA-A2.1-transfected C1R
cell line by P. Romero (Division of Clinical Onco-Immunology, Ludwig
Institute for Cancer Research, Lausanne, Switzerland), HLA-A3-trans-
fected C1R cell line by W. Biddison (Molecular Immunology Section,
National Institute of Neurological Disorders and Stroke, National Institutes
of Health, Bethesda, MD), HLA-B*2705-transfected C1R cell line by J.
Lopez de Castro (Centro de Biologia Molecular Severo Ochoa, Univer-
sidad Autonoma de Madrid, Facultad de Ciencias, Madrid, Spain), and
HLA-B*3501-transfected C1R cell line by M. Takiguchi (Division of Viral
Immunology, Kumamoto University, Kumamoto, Japan). Finally, a HLA-
B*0801-transfected C1R cell line was established, as described previously.
(35). Although the genotype of the majority of these HLA-transfected C1R
cell lines is known, the cell lines will be depicted by their serotype through-
out the manuscript (for example, C1R-B27). Because C1R-A1 cells grad-
ually lose the expression of HLA-A1 on their surface, an enrichment pro-
cedure was performed every 2–3 wk using anti-HLA-A1,36 mAbs
(BIH0331; One Lambda, Canoga Park, CA) together with DNA-linked
anti-mouse Ig beads (Dynal Biotech GmbH, Hamburg, Germany), accord-
ing to manufacturer’s instructions, to ensure a high percentage of HLA-
A1 C1R cells (minimal of 80% HLA-A1 cells).
Serology
Plasma samples were stored at 20°C and tested for the presence of in-
fluenza A virus (H3N2)- and influenza B virus-specific Abs in a hemag-
glutination inhibition assay according to standard methods (19, 20) using
turkey erythrocytes and four hemagglutinating units of virus. The sera were
tested for Abs against 11 vaccine strains of subtype H3N2 used since 1968
and 11 influenza B virus strains (from 1979 till 2001). Ferret sera raised
against the test Ags were used as positive controls.
Influenza viruses and peptides
Sucrose gradient-purified influenza viruses Resvir-9 and B/Harbin/7/94
(kindly provided by CSL, Parkville, Victoria, Australia) were used for
infection of cells. Resvir-9 is a reassortant virus between strains A/Puerto
Rico/8/34 (H1N1) and A/Nanchang/933/95 (H3N2), containing the nucleo-
protein (NP), hemagglutinin, and neuraminidase of A/Nanchang/933/95.
The infectious virus titers of the virus preparations were determined in cell
culture using Madin-Darby canine kidney cells as indicator cells, as de-
scribed previously (21). Peptide analogues of influenza A virus CTL
epitopes were manufactured, HPLC purified, and analyzed by mass spec-
trometry (Eurogentec, Seraing, Belgium). The peptide analogues corre-
spond to the HLA-A1-restricted NP44–52, HLA-A*0201-restricted
M158–66, HLA-A3-restricted NP265–273, HLA-B*0801-restricted NP380–
388, HLA-B*2705-restricted NP383–391, and HLA-B*3501-restricted
NP418–426 epitope. The peptides were dissolved in DMSO at 5.0 mg/ml,
diluted to 100 M in RPMI 1640, and stored at 20°C.
In vitro stimulation of PBMC with influenza virus
Stimulation of PBMC with influenza virus was performed, as described
previously (15). Cells were resuspended at 1  106 cells/ml in R10F and
infected for 1 h at 37°C with Resvir-9 or B/Harbin/7/94, at a multiplicity
of infection (MOI) of 3. Next, the cells were washed once and resuspended
in RPMI 1640 medium supplemented with 10% human AB serum, 2 mM
glutamine, 100 g/ml streptomycin, 100 IU/ml penicillin, and 20 M
2-ME (R10H), and added to uninfected PBMC at a ratio of 1:1 in a 25-cm2
culture flask. After 2 days, rIL-2 (final concentration 50 U/ml; Chiron B.V.,
Amsterdam, The Netherlands) was added and the cells were incubated for
another 6 days at 37°C and used as effector cells in a 51Cr release assay or
intracellular cytokine staining (ICS) assay (see below).
Isolation of CD8 T cells
CD8 T cells were isolated from the effector cell populations by magnetic
sorting, using a CD8 cell selection kit (Dynal Biotech GmbH). First, the
cells were washed once in PBS supplemented with 2.0% FCS (P2F) and
finally resuspended in P2F at a concentration of 1 107/ml. Capture beads
were added to the cell suspension at a bead to CD8 T cell ratio of 8:1.
Following a 30-min incubation at 4°C, the beads/cells were washed six
times with 5.0 ml of P2F. The beads, together with the attached cells, were
reconstituted in 200 l of RPMI 1640 medium with 1.0% FCS. To detach
the cells from the beads, 20 l of DETACHaBEAD (Dynal Biotech
GmBH) was added and incubated for 1 h at 20°C. The released cells were
isolated, washed once in R10F, and used as effector cells in 51Cr release
assays (22).
Preparation of target cells for 51Cr release assay
HLA-A- and -B-matched BLCL, C1R, and C1R cells transfected with var-
ious HLA genes were used as target cells in 51Cr release assays. All cells
were infected with Resvir-9 at a MOI of 3 in RPMI 1640 medium, con-
taining 0.1% BSA, 2 mM glutamine, 100 g/ml streptomycin, and 100
IU/ml penicillin (R0.1B). Following a 1-h infection at 37°C, the cells were
washed once in R10F and incubated in R10F for 16 h at 37°C. The fol-
lowing day, 106 cells were washed once in R0.1B medium and incubated
for 1 h at 37°C with 75 Ci of Na2[51Cr]O4. The cells were then washed
three times in R10F and used as target cells. Uninfected cells of the HLA-
matched BLCL, C1R, and HLA-transfected C1R cell line were included to
determine nonspecific lysis of target cells.
The Ag presentation capacity of HLA-transfected C1R cells was com-
pared with cells of two BLCL. To this end, the minimal peptide concen-
tration was determined for which 50% of the target cells were killed (EC50)
by epitope-specific CTL clones. After a 1-h incubation with Na2[51Cr]O4,
the cells were washed twice in R10F and distributed in 96-well V-bottom
plates. Next, the cells were incubated with a 10-fold serial dilution of the
peptides in R10F for 1 h at 37°C, washed once in R10F, and used as target
cells in a 51Cr release assay. The HLA-A2-, -A3-, -B27-, and -B35-re-
stricted influenza A virus-specific CTL clones were previously described
(23–25), while the HLA-A1- and -B8-restricted influenza A virus-specific
CTL clones were established, as described previously (25).
Intracellular cytokine staining
Influenza virus-stimulated PBMC were also used for ICS assay. One hun-
dred thousand PBMC were incubated in 100 l of R10F containing Gol-
giStop (monensin; BD PharMingen, Alphen a/d Rijn, The Netherlands) and
GolgiPlug (brefeldin; BD PharMingen). In addition, 2  105 influenza
virus-infected (Resvir-9, MOI  3 or B/Harbin/7/94, MOI  1) and un-
infected HLA-matched BLCL cells and C1R cells with or without HLA
transgene were also incubated in 100 l of R10F containing GolgiPlug and
GolgiStop and used as stimulator cells. After 30 min at 37°C, the stimulator
cells were added to the PBMC for 6 h at 37°C. Next, the cells were washed,
stained, and fixed, as previously described (26), using FITC-conjugated
anti-CD8 (Dakocytomation, Glostrup, Denmark), PerCP-conjugated anti-
CD3 (BD Biosciences, Alphen a/d Rijn, The Netherlands), PE-conjugated
anti-IFN- (BD PharMingen), and allophycocyanin-conjugated anti-
TNF- (BD Biosciences) mAb. At least 2000 gated CD3 CD8 T cells
were acquired using a FACSCalibur flow cytometer (BD Biosciences).
Data were analyzed with CellQuestPro (BD Biosciences) and are expressed
as the percentage of cytokine-positive cells following stimulation with in-
fluenza virus-infected cells minus the percentage of cytokine-positive cells
after stimulation with uninfected cells. To determine the percentage of
allele-specific cytokine-positive T cells, the proportion of cytokine-positive
cells following stimulation with C1R control cells is subtracted from the
3 Abbreviations used in this paper: BLCL, B lymphoblastoid cell line; ICS, intracellular
cytokine staining; MOI, multiplicity of infection; NP, nucleoprotein.for publication.
Table I. HLA-A- and -B genotype of donors
Group HLA-A and -B Genotype
No. of
Donors
I A*0101, A*0201, B*0801, B*3501 4
II A*0101, A*0201, B*0801, B*2705 4
III A*0101, A*0301, B*0801, B*3501 5
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percentage of cytokine-positive cells following stimulation with HLA-
transfected C1R cells.
ELISPOT assay
Virus-specific CD8 T cells and their HLA restriction element were also
quantified in ELISPOT assays, which were performed as previously de-
scribed (15). Before stimulation with uninfected and virus-infected C1R
cells expressing single HLA class I molecules, for the induction of IFN-
production, CD8 CD16 cells were isolated from PBMC using
dynabeads.
51Cr release assay
51Cr release assays were performed, as described previously (15). Influenza
A virus-specific CTL clones were added to 5  103 51Cr-labeled target
cells at an E:T cell ratio of 10:1 or 5:1. Isolated CD8 T cells, obtained
from influenza A virus-stimulated PBMC cultures, were also used as ef-
fector cells at E:T ratios of 10:1 to 1.25:1. After 4 h at 37°C, the culture
supernatants were harvested (Skatron Instruments, Sterling, VA) and ra-
dioactivity was measured by gamma counting. The percentage of specific
lysis was calculated with the following formula: ((experimental release 
spontaneous release)/(maximum release  spontaneous release))  100.
The percentage of influenza A virus-specific lysis was calculated from the
percentage of lysis of infected cells minus the percentage of lysis of un-
infected cells of at least three wells.
Flow cytometry
Following isolation of CD8 T cells, the purity of the CD8 T cell pop-
ulation was tested. Approximately 105 cells were washed once in P2F, and
incubated in 50 l of P2F containing anti-CD8, anti-CD4 (Dakocytoma-
tion), and anti-CD3 mAb for 30 min at 4°C. Next, the cells were washed
once in P2F, and at least 104 events were acquired using a FACSCalibur
flow cytometer. The CD8 T cell purity of the isolated CD8 T cells was
generally 90%.
Before 51Cr release and ICS assays, target cells were tested for the
expression of transfected HLA genes. C1R-A1 and C1R-A3 cells were
incubated with biotin-conjugated anti-HLA-A1/36 and anti-HLA-A3
(BIH0269; One Lambda) mAb, respectively, followed by FITC-conjugated
streptavidin (Dakocytomation). C1R-A2, C1R-B8, and C1R-B27 cells
were incubated with FITC-conjugated anti-HLA-A2,28 (FH0037; One
Lambda), anti-HLA-B8 (FH0536A; One Lambda), or anti-HLA-B27
(B27F50X; One Lambda) mAb, respectively. Finally, C1R-B35 were in-
cubated with culture supernatant of hybridoma 4D12 (ATCC HB-178;
American Type Culture Collection, Manassas, VA), and subsequently
stained with FITC-conjugated anti-mouse Ig Fab (Dakocytomation). The
level of HLA expression on C1R and C1R cells with various HLA trans-
genes was determined by flow cytometry using saturating levels of anti-
HLA-ABC Abs (BD PharMingen). All Ab-staining procedures were per-
formed in P2F at 4°C. At least 10,000 cells were acquired with a
FACSCalibur flow cytometer and analyzed with CellQuestPro.
Statistical analysis
To identify statistical differences between IFN- responses restricted by
individual HLA-A or -B alleles, the Student t test was performed. To in-
vestigate preferential HLA-A or -B usage in the three groups of donors, a
Friedman test was performed, comparing the response to individual alleles
with a theoretical random contribution of the four HLA-A and -B alleles.
Differences in ratio IFN- cells and TNF- cells were analyzed with a
univariate ANOVA post hoc analysis. Ratio of IFN-/TNF--positive cells
was determined if both proportions of cytokine-positive cells were more
than 1.0%. Values of p  0.05 were considered statistically significant.
Results
Validation of HLA-transfected C1R cells
Before using C1R cells expressing HLA transgenes as APCs, their
HLA expression and Ag-presenting capacity were tested. As
shown in Fig. 1A, all C1R cells transgenic for individual HLA
genes exhibited HLA class I expression after incubation with an
Ab specific for all HLA-A, -B, and -C alleles. The expression was
in the same order of magnitude as in normal BLCL cells (solid
lines, Fig. 1A). Control C1R cells also exhibited surface expression
of HLA class I molecules to a limited extent as a result of endog-
enous HLA-Cw4 expression (17, 18). This expression was at least
10-fold lower than in the HLA-transfected C1R cells. The expres-
sion of HLA-A or -B molecules by the respective C1R cells was
further confirmed using allele-specific Ab preparations (data not
shown). Furthermore, the HLA expression was not reduced after
infection of these cells with influenza A viruses (data not shown).
The concentration of peptide analogous of CTL epitopes re-
quired to give 50% of the maximum lysis (epitope concentration
(EC)50 values) of target cells by corresponding CTL clones was
used as a measure for Ag-presenting capacity of C1R cells. As
shown in Fig. 1B, the EC50 values ranged from 107 M for the
HLA-B*0801-restricted epitope (NP380–388) to 1010 M for the
HLA-B*3501-restricted epitope (NP418–426). More importantly,
the EC50 values for the HLA-transfected C1R cells were similar or
slightly lower than the EC50 values measured with HLA-matched
BLCL cells, indicating that functional presentation of peptides is
comparable.
Using HLA-transfected C1R cells infected with influenza A vi-
rus, it was demonstrated in a 51Cr release assay that the natural
CTL epitope was liberated from viral proteins and presented to
specific CTL clones (Fig. 1C). In addition, the respective CTL
clones only recognized HLA-transfected C1R target cells express-
ing the matching HLA molecule.
IFN- responses in CD8 T cells restricted by individual
HLA-A and -B alleles
The contribution of individual HLA-A and -B alleles to the influ-
enza A virus-specific CTL response was determined by measuring
the proportion of IFN- CD8 T cells in influenza A virus-spe-
cific PBMC cultures, which were restimulated with HLA-matched
BLCL or C1R cells expressing individual HLA-A and -B alleles.
An example of such an analysis is shown in Fig. 2.
Using this procedure, PBMC of all (n 13) donors were tested.
In donors of group I (HLA-A1, HLA-A2, HLA-B8, HLA-B35),
the proportion of CD8 T cells producing IFN- after stimulation
with HLA-matched BLCL cells was 46% (Fig. 3A). Stimulation
with HLA-transfected C1R cells showed that on average 16.4% of
these cells were restricted by HLA-B*3501. HLA-A*0201-, HLA-
B*0801-, and HLA-A*0101-restricted CD8 T cells accounted for
10.2, 9.2, and 5.5% on average, respectively. No significant dif-
ferences, summarized in Table II, were observed between the fre-
quencies of virus-specific CTL restricted by single HLA-A or -B
alleles in these donors.
In donors of group II (HLA-A1, HLA-A2, HLA-B8, HLA-B27),
on average 41% of the CD8 T cells were IFN- after stimula-
tion with HLA-matched BLCL cells. The majority of these cells
were specific for CTL epitopes presented in the context of HLA-
B*2705 with an average of 23.8% of IFN- CD8 T cells in
these donors (Fig. 3A). This HLA-B*2705-restricted response dif-
fered significantly with the percentages of IFN- CD8 T cells
found after stimulation with C1R-A2 (10.5%, p 0.008), C1R-A1
(2.4%, p 0.002), and C1R-B8 (2.9%, p 0.002). The proportion
of IFN- cells after stimulation with C1R-A2 (10.5%) also dif-
fered from the responses to C1R-A1 ( p  0.016) and C1R-B8
( p  0.02).
In donors of group III (HLA-A1, HLA-A3, HLA-B8, HLA-
B35), the proportion of CD8 T cells producing IFN- after stim-
ulation with HLA-matched BLCL cells was on average 32% (Fig.
3A). Most of the influenza A virus-specific CD8 T cells were
specific for CTL epitopes presented by HLA-B*3501 (15.9%
IFN- cells), followed by those specific for C1R-A3 (10.0%)-,
C1R-B8 (7.8%)-, and C1R-A1 (3.5%)-restricted epitopes. The av-
erage percentage of IFN- cells of HLA-A*0101-restricted
CD8 T cells was significantly lower than the proportion of cells
of restricted HLA-A*0301 ( p  0.007).
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We also compared the magnitude of the responses restricted by
shared alleles between donors of different groups. The HLA-
B*0801-restricted response was significantly lower in donors of
group II (2.9%) than in those of group III (7.8%, p  0.04) and to
a lesser extent in those of group I (9.1%, p  0.1). The HLA-
A*0101-restricted response in group I (5.5%) did not significantly
differ from that observed in groups II (2.4%) and III (3.5%). Also,
no differences were found between groups in the proportion of
IFN- CD8 T cells restricted by HLA-A*0201 (10.2 vs 10.5%)
or HLA-B*3501 (16.4 vs 15.9%).
To demonstrate preferential HLA usage in individual donors,
pie charts were constructed (Fig. 3B), illustrating the IFN- re-
sponses for each HLA allele (shades of gray) within the CD8 T
cell population (entire circle). Not all CD8 T cells produced
IFN- upon stimulation with virus-infected stimulator cells (open
part). In donors of group I, an HLA-A*0201-restricted response
was always found, which was dominant in donors 1 and 2. HLA-
B*3501 was found to be an immunodominant allele in two other
donors (3 and 4). Subdominant HLA-B*0801-restricted responses
were found in all donors, while the HLA-A*0101-restricted re-
sponse was detected in 3 of 4 donors. Preferential HLA usage in
this group of donors was not demonstrated ( p  0.165).
In all four donors of group II, a dominant HLA-B*2705-re-
stricted IFN- response was observed in addition to the HLA-
A*0201-restricted IFN- response. The HLA-A*0101- and HLA-
B*0801-restricted IFN- responses only contributed, to a limited
extent, to the influenza A virus-specific CTL response in these
donors. The preferred usage of certain HLA class I alleles in these
donors was statistically significant ( p  0.011).
In group III, the most dominant response was restricted by
HLA-B*3501 in donors 1, 2, 4, and 5, while in donor 3 this
response was only minor (Fig. 3B). An HLA-A*0301-restricted
response was observed in all five donors and was found immu-
nodominant in three donors. Also, the HLA-A*0101- and
-B*0801-restricted responses were detected in all donors, but
were found to be subdominant. Again, the preferred recognition
of certain alleles in these donors was statistically significant
( p  0.005).
FIGURE 1. Expression of foreign HLA-A or -B alleles on C1R cells. A, HLA expression on BLCL, C1R, and HLA-transfected C1R cells. HLA
expression was measured with saturating levels of anti-HLA-ABC mAb. The level of HLA expression (fluorescence intensity, solid line) is shown for cells
of BLCL, C1R, and HLA-transfected C1R cell lines. Unstained cells are shown as dotted lines in the figures. B, HLA-transfected C1R cell lines stimulate
influenza A virus-specific CTL clones. HLA-transfected C1R cells (open symbols) and two HLA-matched BLCL (closed symbols) were used as target cells
in a 51Cr release assay after a 1-h incubation with 10-fold serial dilutions of peptide analogous of epitopes. C1R-A1 cells were incubated with the NP44–52
epitope; C1R-A2 cells with the M158–66 epitope; C1R-A3 cells with the NP265–273 epitope; C1R-B8 cells with the NP380–388 epitope; C1R-B27 cells with
NP383–391 epitope; and finally, C1R-B35 cells with the NP418–426 epitope and used as target cells for CTL clones specific for the respective epitopes (E:T
ratio of 10:1). C, HLA-restricted recognition of influenza A virus-infected HLA-transfected C1R cells by virus-specific CTL. HLA-transfected C1R cells,
C1R control cells, and three different BLCL cells were infected with Resvir-9 (MOI  3) and used as target cells in a 51Cr release assay. Influenza A
virus-specific CTL clones (see above) were used as effector cells at an E:T ratio of 10:1. The results are given as the percentage of lysis of each target cell
minus the lysis of virus-infected C1R cells. HLA-genotyped BLCL were included as controls to confirm the HLA restriction of the influenza A virus-specific
CTL clones. The percentage of lysis, represented by different shades of gray, is (darkest to lightest) (100–80%; 80–60%; 60–40%; 40–20%; 20–0%).
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The sum of the IFN- CD8 T cells observed after stimulation
with four different C1R cell lines expressing the four HLA-A and
-B alleles was compared with the number of IFN- CD8 T cells
observed after stimulation with HLA-matched BLCL cells. As
shown in Fig. 3B (bar charts), the sum of the responses restricted
by individual alleles () almost accounted for the total influenza
A virus-specific response (f) in most cases. In 11 of 13 donors, the
difference was less than 10% and only in donor 4 of group II and
donor 3 of group III the differences exceeded 10%.
HLA-A- and -B-restricted lysis of target cells by CD8 CTL
The contribution of individual HLA-A and -B alleles in the rec-
ognition of infected target cells by influenza A virus-specific CTL
was also studied in 51Cr release assays, using infected and unin-
fected HLA-transfected C1R cells and HLA-matched BLCL cells
(Fig. 4). The CD8 effector cell populations obtained from donors
in group I recognized HLA-matched BLCL, C1R-A1, and C1R-A2
cells to a similar extent (average percentage of 65%). The average
percentages of specific lysis of C1R-B8 and C1R-B35 were 40 and
30%, respectively.
Influenza A virus-specific CD8 T cells obtained from donors
in group II lysed influenza virus-infected C1R-B27 cells efficiently
(average percentage of 70%). The lysis of virus-infected C1R-A2
and C1R-A1 ranked second and third, respectively. Finally, the
lysis of infected C1R-B8 cells was lower than the percentage lysis
of C1R-B27 ( p  0.001) and C1R-A2 ( p  0.02).
CD8 effector cells obtained from donors in group III did not
exhibit a clear preferred HLA usage in the recognition of their
target cells.
HLA-A- and -B-restricted IFN- responses specific for influenza
B virus
The IFN- response restricted by HLA-A and -B alleles was de-
termined in PBMC of donors of group II (HLA-A1, HLA-A2,
HLA-B8, and HLA-B27) stimulated with influenza B virus, to in-
vestigate whether HLA-B*2705 was also the preferred allele in
response to another type of influenza virus. On average, 41%
IFN- CD8 T cells were detected after restimulation with in-
fluenza B virus-infected HLA-matched BLCL cells (Fig. 5). The
majority of these cells recognized their epitopes in the context of
HLA-B*0801 (22.7%), followed by the HLA-B*2705 (7.4%)-,
HLA-A*0101 (2.4%)-, and HLA-A*0201-restricted (2.3%) re-
sponses. The proportion of HLA-B*0801-restricted IFN- CD8
T cells was significantly greater than the proportion of C1R-A1
( p  0.05)- or C1R-A2 ( p  0.05)-restricted IFN- CD8 T
cells. The HLA-A*0101- and HLA-A*0201-restricted IFN- re-
sponses were also significantly smaller than the HLA-B*2705-re-
stricted response ( p  0.017 and p  0.002, respectively).
IFN- and TNF- expression in influenza A virus-specific CTL
restricted by individual HLA-A and -B alleles
The expression of TNF- was determined as a third functional
parameter after restimulation of influenza A virus-stimulated
PBMC with HLA-matched BLCL and HLA-transfected C1R cells.
The ratio between percentage of IFN- and percentage of
TNF- cells within the CD8 T cell fraction for each individual
for the different HLA-transfected C1R cells and HLA-matched
BLCL cells was calculated (data not shown). The ratio of IFN-
and TNF- cells following stimulation with HLA-matched
BLCL cells is on average 1.1, indicating that most virus-specific
cells produce both cytokines upon restimulation. However, stim-
ulation with HLA-transfected C1R cells resulted in ratios starting
from 1.2 for C1R-B27 to 1.8 for C1R-A2, C1R-A3, C1R-B8, and
C1R-B35, while stimulation with C1R-A1 cells resulted in an av-
erage ratio of 0.7. This indicates that some HLA-A*0101-re-
stricted influenza A virus-specific CTL produce TNF-, but not
IFN-. This ratio was significantly different from the average ratio
of C1R-A2 ( p 0.011), C1R-B8 ( p 0.001), and C1R-B35 ( p
0.001).
Discussion
The contribution of individual HLA-A and -B alleles in influenza
virus-specific CTL responses was determined in groups of HLA
class I-matched donors. It was shown that influenza virus-stimu-
lated PBMC of HLA-A- and -B-matched donors preferentially rec-
ognized certain HLA alleles, which depended on the type of virus
studied. Furthermore, it was demonstrated that cytokine produc-
tion profiles of CD8 CTL depended on their HLA class I restric-
tion elements.
Before investigation of CTL responses restricted by individual
HLA-A and -B alleles, the use of HLA-transfected C1R cells as
APC was validated. The level of expression of HLA molecules
was similar in the different C1R cells as measured with saturating
amounts of Ab. These cells were also capable of processing and pre-
senting influenza A virus-specific CTL epitopes to a similar extent as
EBV-transformed BLCL. In addition, only small differences in sus-
ceptibility of the individual C1R cells for infection with influenza A
virus were found (between 55 and 80% infected), with the exception
of C1R-B35. This, however, did not interfere with our ICS assay,
because an excess number of stimulator cells was used to stimulate
influenza virus-specific CTL in the in vitro stimulated PBMC cul-
tures. In contrast to the use of BLCL matched for a single HLA allele,
the use of C1R expressing single HLA alleles prevents possible com-
petition for processing/presentation between overlapping epitopes
(27). In EBV-transformed BLCL cells or C1R cells, competition for
available HLA-A or -B alleles between epitopes from influenza virus
and EBV may occur. For example, an immunodominant HLA-
B*0801-restricted CTL epitope of EBV (EBNA3A325–333) could in-
terfere with the presentation of HLA-B*0801-restricted influenza vi-
rus epitopes. However, influenza A virus-infected C1R-B8 cells were
readily killed by HLA-B*0801-restricted influenza A virus-specific
FIGURE 2. IFN- expression in CD8 T cells after stimulation of
PBMC with influenza virus. PBMC expanded after stimulation with influ-
enza A virus were restimulated with HLA-matched BLCL, C1R, and HLA-
transfected C1R cells infected with influenza A virus (Resvir-9) at a ratio
of 1:2 for 6 h in the presence of monensin and brefeldin. Stimulation with
uninfected cells was used as negative controls. Virus-specific CTL re-
stricted by individual alleles were visualized after staining with different
fluorochrome-conjugated mAb specific for CD8, CD3, and IFN-. The dot
plots show an example of the expression of IFN- in T cells following
stimulation of PBMC of donor 1 (group I) with infected and uninfected
cells of an HLA-matched BLCL and C1R control cells and infected C1R
cells expressing HLA-A1, HLA-A2, HLA-B8, or HLA-B35. The propor-
tion of IFN- cells in the CD3 CD8 T cell fraction is indicated.
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CTL, indicating that competition between epitopes of these two vi-
ruses does not constitute a significant problem.
Using the HLA-transfected C1R cell lines, it was shown that the
influenza A virus-specific CTL response in these donors measured
by intracellular IFN- staining was dominated by HLA-B*2705-
and HLA-B*3501-restricted CTL in groups II and I/III, respec-
tively. Based on previous findings with synthetic peptides (15), it
was anticipated that the HLA-A*0201-restricted response, present-
ing the immunodominant epitope M158–66, would be recognized
preferentially. Therefore, the observed hierarchy of virus-specific
responses indicates that other yet unidentified HLA-B*2705- and
HLA-B*3501-restricted epitopes exist. Recently, an immunodom-
inant HLA-B*3501-restricted epitope (NP418–426) was identified
(25), which may have contributed to the preferred usage of HLA-
B*3501 in the CTL response. In addition to the dominance of
HLA-B27 and HLA-B35, a large proportion of T cells was specific
for epitopes presented by HLA-A*0201 and HLA-A*0301. Most
likely the presentation of the immunodominant epitope M158–66
has contributed to the dominance of the HLA-A*0201-restricted
response. The large proportion of HLA-A*0301-restricted CTL
indicates that more unknown immunodominant epitopes exist, be-
cause the HLA-A*0301-restricted NP265–273 epitope has been
shown to be subdominant in response to influenza A viruses (15).
Indeed, a novel HLA-A3-restricted CTL epitope was identified
recently, which could contribute to the influenza A virus-specific
CTL response (28). Finally, the IFN- response specific for
epitopes presented in the context of HLA-A*0101 and HLA-
B*0801 contributed little to the overall influenza A virus-specific
CTL response, which is in agreement with previous work (29). The
small contribution of these alleles to the overall CTL response
could be caused by the presence of alleles HLA-B*2705 or HLA-
B*3501 presenting immunodominant epitopes. This hypothesis
FIGURE 3. Influenza A virus-specific IFN- responses restricted by individual HLA-A and -B alleles in three groups of HLA-A- and -B-matched
donors. A, Virus-specific effector cells expanded from PBMC were restimulated with influenza A virus-infected and uninfected HLA-matched BLCL, C1R,
and HLA-transfected C1R cells at a ratio of 1:2 for 6 h in the presence of monensin and brefeldin. Virus-specific CTL were visualized after staining for
CD8, CD3, and IFN-. The proportion of IFN- cells in the CD3 CD8 T cell fraction after stimulation with infected HLA-matched BLCL cells (6358,
7482, and 5507) or C1R cells expressing individual HLA-A or -B alleles is shown, as indicated. The proportion of influenza A virus-specific IFN- CD8
T cells was calculated by subtracting the percentage of IFN- CD8 T cells following stimulation with uninfected cells and virus-infected C1R control
cells from the percentage of IFN- CD8 T cells obtained after stimulation with virus-infected HLA-transfected C1R cells. B, The contribution of HLA-A
and -B alleles in the influenza A virus-specific CTL response. The different parts in the pie charts represent the proportion of CD8 T cells restricted by
individual HLA alleles (shades of gray), starting with HLA-A*0101 and going counterclockwise via HLA-A*0201 in groups I and II or HLA-A*0301 in
group III, and HLA-B*0801 to HLA-B*2705 in group II and HLA-B*3501 in groups I/III. The proportion of unresponsive CD8 T cells is also shown
(white area). The bar charts indicate the percentage of influenza A virus-specific IFN- CD8 cells after stimulation with HLA-matched BLCL cells (f)
or the sum of the percentage of IFN- CD8 T cells after stimulation with C1R cells transfected with individual HLA-A and -B alleles (). The average
proportion of IFN- CD8 T cells of all donors in groups I-III is shown in A by horizontal bars ().
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was supported by a high proportion of IFN- HLA-B*0801-re-
stricted cells in an HLA-A*0101, HLA-B*0801 homozygous do-
nor (data not shown). In addition, the HLA-B*0801-restricted re-
sponse was lower in donors of group II (HLA-B27 donors) than
in donors in the two other groups (HLA-B35 donors), which is in
agreement with the poor recognition of the HLA-B*0801-re-
stricted NP380–388 epitope in HLA-B27 individuals (15, 27).
These data also indicate that more immunodominant high affinity
HLA-B*0801-restricted epitopes are not existing for influenza A
virus.
Changes in epitope specificity of the virus-specific CTL re-
sponse as a result of differences in HLA expression profiles were
previously reported in mice infected with influenza A virus (3, 11,
30). In these studies, the expression of an H-2Kb allele (either
transgenic or through breeding with C57BL mice) resulted in a
reduced H-2k-restricted response.
A possible skewing of the CTL response in favor of certain
HLA restrictions during in vitro stimulation of PBMC in the pres-
ence of rIL-2 was excluded, because it was found in a previous
study that the hierarchy of peptide-specific CTL responses mea-
sured ex vivo in PBMC correlated with the hierarchy of lytic ac-
tivity measured after in vitro expansion of virus-specific CTL us-
ing the same stimulation protocol (15). Furthermore, ELISPOT
assays were conducted with CD8 CD16 cells isolated from
PBMC of several donors from groups I and II to determine pref-
erential HLA usage ex vivo. In the donors of group II, the same
hierarchy of preferred HLA usage was observed ex vivo, as was
observed after in vitro expansion of virus-specific CTL. In group
I, without preferential HLA usage after in vitro expansion of virus-
specific cells, ex vivo no-preferred HLA usage was also demon-
strated (data not shown).
In a previous study (15), we reported a lower influenza A virus-
specific immune response in HLA-A*0201-negative donors (group
III). Also in the current study, the average number of IFN- cells
following restimulation with HLA-matched BLCL is lower in
HLA-A*0201-negative donors than in HLA-A*0201-positive do-
nors, although this difference was not statistically significant ( p 
0.28). This is partly explained by the exclusion of two HLA-
A*0201-negative donors with an HLA-B*3503 instead of an
HLA-B*3501 genotype.
FIGURE 4. Lytic activity of CTL restricted by individual HLA-A and
-B alleles. CD8 cells were isolated from influenza A virus-stimulated
PBMC and used as effector cells in a 51Cr release assay. The lytic activity
of virus-specific CTL is calculated as the percentage of lysis of influenza
A virus-infected HLA-matched BLCL (6358, 7482, 5507), C1R, and HLA-
transfected C1R cells minus the lysis of uninfected cells, at an E:T cell ratio
of 5:1 for HLA-matched BLCL cells and 10:1 for C1R and HLA-trans-
fected C1R cells. Each graph represents a group of HLA-A and -B identical
donors, and each donor is depicted by a different symbol. Donor 4 in group
I was excluded because not sufficient cells were recovered to perform the
assay. The average percentage of lysis of target cells by effector cells of the
respective donors is shown ().
FIGURE 5. Influenza B virus-specific IFN- responses restricted by in-
dividual HLA-A and -B alleles in donors of group II. Effector cells were
restimulated with influenza B virus-infected (MOI  1) and uninfected
HLA-matched BLCL cells, C1R cells, and HLA-transfected C1R cells at a
ratio of 1:2 for 6 h in the presence of monensin and brefeldin. Influenza B
virus-specific CTL were visualized after staining for CD8, CD3, and
IFN-. The data represent the proportion of influenza B virus-specific
IFN- cells in the CD3 CD8 T cell fraction after stimulation with
HLA-matched BLCL cells (7482) and C1R cells expressing individual
HLA alleles, as indicated. In addition, the sum of the proportion of IFN-
CD8 T cells restricted by individual HLA-A and -B alleles is depicted for
each individual. The average proportion of IFN- CD8 T cells of all
donors in group II is shown by a horizontal bar (). The symbols represent
the four different donors from this group.





p Value p Value
I No 0.165 NDc ND
II Yes 0.011d A2  A1e 0.016
A2  B8 0.02
B27  A1 0.008
B27  A2 0.002
B27  B8 0.002
III Yes 0.005 A3  A1 0.007
a The preferential HLA usage was determined in donors of groups I to III, using
the percentage of IFN- CD8 T cells restricted by single HLA-A or -B alleles.
b The average percentage of virus-specific CTL restricted by individual HLA-A or
-B alleles, as measured by intracellular IFN- staining, was compared.
c ND, no significant differences detected.
d Values of P  0.05 are considered statistically significant.
e A2  A1 indicates that the percentage of virus-specific HLA-A*0201-restricted
CTL is higher than the percentage restricted by HLA-A*0101.
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Using influenza B virus for the stimulation of PBMC, we dem-
onstrated that the preferential HLA usage is dependent on the virus
studied. In contrast to the influenza A virus-specific CTL response,
the HLA-B*0801-restricted response specific for influenza B virus
was highly immunodominant, followed by HLA-B*2705. The
HLA-A*0101- and HLA-A*0201-restricted responses were shown
to contribute little to the overall influenza B virus-specific re-
sponse. It is difficult to correlate these responses to known (im-
munodominant) epitopes because only four influenza B virus CTL
epitopes are known (31, 32), of which three are presented in the
context of HLA-B8 (32). These data indicate that the available
epitope repertoire determines the outcome of the CTL response
and preferred HLA usage.
In contrast to other studies addressing the preferential use of
HLA molecules in CTL responses, we used virus-infected human
cells expressing a single HLA allele, which accounts for the full
repertoire of CTL epitopes presented by these HLA molecules.
The preferential usage of certain alleles in the virus-specific CTL
response has also been reported for EBV-specific CTL responses.
These data demonstrated that certain HLA class I alleles were
dominantly recognized, such as HLA-B8, HLA-A11, or HLA-
B44, while HLA-A1 was not (7, 9). For HIV-specific CTL re-
sponses, it was shown with synthetic peptides that the HLA-A2-
restricted response hardly contributed to the overall HIV-specific
response (12, 14).
Most of these studies used IFN- production to identify epitope-
specific CTL. However, our data suggest that CTL differ in their
ability to produce cytokines depending on the epitopes recognized
and/or the HLA molecules presenting these epitopes. Influenza A
virus-specific HLA-A*0101-restricted CTL produced less IFN-
and more TNF- than CTL restricted by other HLA molecules.
Therefore, some caution should be exercised in interpreting fre-
quencies of CTL based on IFN- production alone. The preferred
HLA usage, as demonstrated by quantification of virus-specific
IFN- CD8 T cells and the lytic activity, of these cells differed,
which also could be attributed to functional differences of HLA-
A1- and HLA-B35-restricted CTL in particular. To our knowl-
edge, this is the first study to identify differences in cytokine pro-
duction in CD8 CTL effector cell populations. Previous studies
identified functional differences between EBV-, CMV-, and HIV-
specific CTL, based on perforin and surface marker staining (33,
34). These studies also showed reduced killing of two HIV tet-
ramer-positive cell populations in comparison with a CMV tet-
ramer-positive population. Our data provide evidence also that
acute viral infections, like influenza virus, induce functionally dif-
ferent CD8 CTL populations. At present, it is unclear what the
underlying mechanism is for differential cytokine expression in
virus-specific CTL and how epitope specificity and the HLA mol-
ecules control this. Additional studies are required to further char-
acterize these functional differences in CTL function and to inves-
tigate the implications of differential cytokine expression.
Thus, collectively, the present study has shown in donors of
well-defined HLA genotypes that: 1) in response to virus infection,
CTL responses are induced that use certain HLA molecules pref-
erentially, depending on the available repertoire of CTL epitopes;
2) CTL exhibit differential cytokine expression depending on their
epitope specificity and/or HLA restriction.
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